Artificial Intelligence (AI) and deep learning have already transformed several aspects of small molecule drug design. Recent advances in the area are now also impacting more complex tasks, such as design and optimisation of antibodies. As a result, 2022 saw a breakthrough when the first ever computationally designed antibody created by Israel-based Biolojic design entered clinical trial, further fuelling the interest of biopharma companies.